{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:15:56Z","timestamp":1786997756775,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["103-CDC-C-114-112301"],"award-info":[{"award-number":["103-CDC-C-114-112301"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["104-CDC-C-114-123201"],"award-info":[{"award-number":["104-CDC-C-114-123201"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["105-CDC-C-114-00102"],"award-info":[{"award-number":["105-CDC-C-114-00102"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.tube.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T12:51:41Z","timestamp":1528375901000},"page":"121-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan"],"prefix":"10.1016","volume":"111","author":[{"given":"Hsin-Yun","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-5548","authenticated-orcid":false,"given":"Lih-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-8276","authenticated-orcid":false,"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-7253","authenticated-orcid":false,"given":"Sheng-Yuan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-366X","authenticated-orcid":false,"given":"Jann-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2018.05.013_bib1","series-title":"Annual TB report","author":"WHO","year":"2017"},{"key":"10.1016\/j.tube.2018.05.013_bib2","series-title":"Global strategy and targets for tuberculosis prevention, care and control after","author":"World Health Organization 67th World Health Assembly","year":"2015"},{"key":"10.1016\/j.tube.2018.05.013_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM200107193450307","article-title":"Management of tuberculosis in the United States","volume":"345","author":"Small","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.05.013_bib4","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tube.2018.05.013_bib5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.05.013_bib6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2016.10357","article-title":"Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US preventive services task force","volume":"316","author":"Kahwati","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tube.2018.05.013_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib8","series-title":"Taiwan tuberculosis control report","author":"Centers for Disease Control Ministry of Health and Welfare R.O.C. (Taiwan)","year":"2013"},{"key":"10.1016\/j.tube.2018.05.013_bib9","unstructured":"Centers for Disease Control Ministry of Health and Welfare R.O.C. (Taiwan). Guidelines on the use of 3HP for latent tuberculosis infection. Available at: http:\/\/www.cdc.gov.tw\/downloadfile.aspx?fid=3CBAABAD2D4F1933. Accessed Nov 12 2017."},{"key":"10.1016\/j.tube.2018.05.013_bib10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.tube.2018.05.013_bib11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jinf.2011.04.005","article-title":"Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load","volume":"62","author":"Wang","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.tube.2018.05.013_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tube.2018.05.013_bib13","series-title":"Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0","year":"2009"},{"key":"10.1016\/j.tube.2018.05.013_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tube.2018.05.013_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent Mycobacterium tuberculosis infection","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2018.05.013_bib18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2018.05.013_bib19","doi-asserted-by":"crossref","first-page":"e4126","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.tube.2018.05.013_bib20","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/cid\/cix725","article-title":"Management of latent tuberculosis infection among healthcare workers: 10-year experience at a single center","volume":"65","author":"Arguello Perez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib22","doi-asserted-by":"crossref","first-page":"e2024","DOI":"10.7205\/MILMED-D-17-00024","article-title":"Use of rifapentine and isoniazid directly observed therapy for the treatment of latent tuberculosis infection in a military clinic","volume":"182","author":"Jinbo","year":"2017","journal-title":"Mil Med"},{"key":"10.1016\/j.tube.2018.05.013_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1097\/TP.0000000000001329","article-title":"Twelve-week rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates","volume":"101","author":"Simkins","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.tube.2018.05.013_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw082","article-title":"Predictors of latent tuberculosis infection treatment after introduction of a new regimen: a retrospective cohort study at an inner city clinic","volume":"3","author":"Yamin","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/cid\/ciw126","article-title":"Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the United States and Canada","volume":"62","author":"Moro","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2018.05.013_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tube.2018.05.013_bib28","series-title":"Surveillance of severe adverse events on once-weekly rifapentine plus high-dose isoniazid for latent tuberculosis infection treatment in Taiwan","author":"Lee","year":"2016"},{"key":"10.1016\/j.tube.2018.05.013_bib29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2018.05.013_bib30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2215\/CJN.01790210","article-title":"High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test","volume":"5","author":"Lee","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.tube.2018.05.013_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/thoraxjnl-2012-202208","article-title":"Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates","volume":"68","author":"Chan","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.tube.2018.05.013_bib32","doi-asserted-by":"crossref","first-page":"16300","DOI":"10.1038\/s41598-017-16559-z","article-title":"Epidemiology and predictors of NTM pulmonary infection in taiwan - a retrospective, five-year multicenter study","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147297921830115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147297921830115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T15:45:15Z","timestamp":1568994315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147297921830115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":32,"alternative-id":["S147297921830115X"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2018.05.013","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}